Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

180.38 +0.97 (+0.54%)
Streaming Delayed Price Updated: 2:07 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,... 
Via Benzinga
Expert Ratings For Natera
Within the last quarter, Natera (NASDAQ:NTRA) has observe... 
Via Benzinga
Natera Sees Deeper Operating Losses In Q2 On Higher Commercialization Costs For New Product Offerings
Natera Inc (NASDAQ: NTRA) expects 2Q'21 revenues of approximately $138 million to $141 million, equivalent to around 60% Y/Y growth. The Company's revenue... 
Via Benzinga
Analyst Ratings For Natera
Within the last quarter, Natera (NASDAQ:NTRA) has observed... 
Via Benzinga
Expert Ratings for Natera
Analysts have provided the following ratings for Natera (NASDAQ:NTRA) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 1 0 0... 
Via Benzinga
Natera: Q1 Earnings Insights
Shares of Natera (NASDAQ:NTRA) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 64.44% over the past year to ($0.74),... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
This Explosive Biotech Is Taking On a Huge New Market
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space. 
Via The Motley Fool
10 Biggest Price Target Changes For Monday
SVB Leerink raised Natera, Inc. (NASDAQ:NTRA) pr... 
Via Benzinga
Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera
From Foundation Medicine
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
Exact Sciences' First-Quarter Results Show Its Strength Under Pressure
Despite ongoing pandemic-related headwinds, the medical diagnostic test maker's revenue grew. So how will it perform as those headwinds dissipate? 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers T2 Biosystems (NASDAQ:TTOO) share... 
Via Benzinga
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Cramer Gives His Opinion On ContextLogic, Microvision And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he bets there could be a bit of a run in ContextLogic Inc. (NASDAQ: WISH) because 40% of the float is shorted... 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.